검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Entrectinib |
Overview Company | Cancer Research UK |
Overview Modality | ADC |
Overview Target | Advanced Breast Carcinoma |
Overview Indication | Haematological Malignancy; Solid Tumour |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | inhibits tropomyosin receptor |
MoA Biomarker | CD206 expression |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | A systematic evaluation of the efficacy and safety of entrectinib in anaplastic thyroid carcinoma.. Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with limited treatment options and poor responsiveness to conventional chemotherapy. In this study, we found that TrkA expression was markedly elevated in clinical ATC tissues compared with adjacent normal thyroid tissue. Knockdown… |
Clinical Primary efficacy | ORR 11.5% |
Clinical ORR | 11.5% |
Clinical PFS | 4.24 |
Clinical Result source | ClinicalTrials.gov NCT04632992 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Entrectinib |
Overview Company | Cancer Research UK |
Overview Modality | ADC |
Overview Target | Advanced Breast Carcinoma |
Overview Indication | Haematological Malignancy; Solid Tumour |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | inhibits tropomyosin receptor |
MoA Biomarker | CD206 expression |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | A systematic evaluation of the efficacy and safety of entrectinib in anaplastic thyroid carcinoma.. Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with limited treatment options and poor responsiveness to conventional chemotherapy. In this study, we found that TrkA expression was markedly elevated in clinical ATC tissues compared with adjacent normal thyroid tissue. Knockdown… |
Clinical Primary efficacy | ORR 11.5% |
Clinical ORR | 11.5% |
Clinical PFS | 4.24 |
Clinical Result source | ClinicalTrials.gov NCT04632992 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교